2017
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
Pusztai L, Chung J, Young L, Schrock A, Hartmaier R, Frampton G, Gay L, Stephens P, Miller V, Ali S, Ross J, Vahdat L, O'Shaughnessy J. Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC). Journal Of Clinical Oncology 2017, 35: 1016-1016. DOI: 10.1200/jco.2017.35.15_suppl.1016.Peer-Reviewed Original ResearchAromatase inhibitor therapyMetastatic breast cancerGenomic profilingCommon genomic alterationsGenomic alterationsTreatment informationTreatment of MBCCo-occurring genomic alterationsConcurrent genomic alterationsPrior chemotherapyInhibitor therapyD538GBreast cancerKinase fusionsTherapeutic approachesClinical careClinical decision
2010
The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches
Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resistance Updates 2010, 13: 99-108. PMID: 20739212, DOI: 10.1016/j.drup.2010.08.001.Peer-Reviewed Original ResearchConceptsTumor initiating cellsInitiating cellsCancer cellsLong-term outcomesBreast cancer recurrenceFuture therapeutic approachesTumor-stromal interactionsBreast cancer cellsHedgehog inhibitor cyclopamineNeoadjuvant chemotherapyResidual diseaseEffective therapyCancer recurrenceBreast cancerTherapeutic approachesInhibitor lapatinibInhibitor cyclopamineTherapy resistanceRegulation of tumorChemical library screenDrug resistanceChemotherapy-resistant subpopulationMultidrug resistanceNovel targetResistant subpopulations